Chicken IgY Antibodies Provide Mucosal Barrier against SARS-CoV-2 Virus and Other Pathogens
- PMID: 33899350
Chicken IgY Antibodies Provide Mucosal Barrier against SARS-CoV-2 Virus and Other Pathogens
Abstract
This mini review includes two case descriptions. It introduces the use of chicken egg yolk antibody (IgY) solutions in the prevention and cure of viral and bacterial infections. Application for the protection against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), rotavirus, and influenza viruses, as well as for the eradication of Pseudomonas aeruginosa, caries, various enteric bacteria and other pathogens, and toxins have been developed. This approach is a fast, reliable, safe, and tested method for producing molecular shield and protection against emerging pathogens and epidemics. In the current pandemic situation caused by coronavirus disease-2019 (COVID-19), this method of passive immunization could be applied for rapid protection against modifiable agents. The specific IgY antibodies start to accumulate into egg yolks about 3 weeks after the immunization of the chicken. The product can be collected safely, as the antigen is not found in the eggs. This method for microbial safety uses natural means and commonly used food substances, which have been tested and could be produced for both blocking epidemics and applying personalized medicine.
Similar articles
-
An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.Int Immunopharmacol. 2020 Aug;85:106654. doi: 10.1016/j.intimp.2020.106654. Epub 2020 Jun 3. Int Immunopharmacol. 2020. PMID: 32512271 Free PMC article. Review.
-
Chicken egg yolk antibodies as therapeutics in enteric infectious disease: a review.J Med Food. 2002 Fall;5(3):159-69. doi: 10.1089/10966200260398198. J Med Food. 2002. PMID: 12495588 Review.
-
Passive immunization with hyperimmune egg-yolk IgY as prophylaxis and therapy for poultry diseases--A review.Anim Health Res Rev. 2015 Dec;16(2):163-76. doi: 10.1017/S1466252315000195. Epub 2015 Nov 16. Anim Health Res Rev. 2015. PMID: 26568433 Review.
-
Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections.Immunol Res. 2000;21(1):1-6. doi: 10.1385/ir:21:1:1. Immunol Res. 2000. PMID: 10803878 Free PMC article. Review.
-
Efficient Production of Human Norovirus-Specific IgY in Egg Yolks by Vaccination of Hens with a Recombinant Vesicular Stomatitis Virus Expressing VP1 Protein.Viruses. 2019 May 16;11(5):444. doi: 10.3390/v11050444. Viruses. 2019. PMID: 31100802 Free PMC article.
Cited by
-
SARS-CoV-2-specific immunoglobulin Y antibodies are protective in infected mice.PLoS Pathog. 2022 Sep 19;18(9):e1010782. doi: 10.1371/journal.ppat.1010782. eCollection 2022 Sep. PLoS Pathog. 2022. PMID: 36121829 Free PMC article.
-
IgY antibodies: The promising potential to overcome antibiotic resistance.Front Immunol. 2023 Jan 20;14:1065353. doi: 10.3389/fimmu.2023.1065353. eCollection 2023. Front Immunol. 2023. PMID: 36742328 Free PMC article. Review.
-
Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases.Front Immunol. 2021 Jun 9;12:696003. doi: 10.3389/fimmu.2021.696003. eCollection 2021. Front Immunol. 2021. PMID: 34177963 Free PMC article. Review.
-
IgY Antibodies as Biotherapeutics in Biomedicine.Antibodies (Basel). 2022 Sep 29;11(4):62. doi: 10.3390/antib11040062. Antibodies (Basel). 2022. PMID: 36278615 Free PMC article. Review.
-
Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19.Front Immunol. 2022 May 10;13:881604. doi: 10.3389/fimmu.2022.881604. eCollection 2022. Front Immunol. 2022. PMID: 35664008 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous